A previous study also demonstrated that azelnidipine significantly decreased plasma levels of monocyte chemoattractant protein-1, IL-6, hsCRP, TNF-α, 8-epi-prostaglandin F2α, and 8-hydroxydeoxyguanosine in patients with diabetic nephropathy [22]. Here, IL6 is linked to diabetic kidney disease.